Hyperbilirubinemia Drug Trials Should Target High-Risk Population
Drug development for the prevention of hyperbilirubinemia in newborns should focus on high-risk populations, FDA's Anti-Infective Drugs Pediatric Subcommittee said June 11
Drug development for the prevention of hyperbilirubinemia in newborns should focus on high-risk populations, FDA's Anti-Infective Drugs Pediatric Subcommittee said June 11